$3,735,000 partnership with Dr. Chris Ryerson to investigate ways to slow the progression of pulmonary fibrosis
Dr. Chris Ryerson, a clinical respirologist at St. Paul’s Hospital and Assistant Professor at UBC, studies pulmonary fibrosis, a devastating disease that affects 5 million people worldwide marked by progressive loss of lung function. Dr. Ryerson designed a clinical trial to investigate the optimal method of exercising for pulmonary fibrosis patients as a means to slow progression of the disease. Boehringer Ingelheim have generously contributed $3,735,020 to fund the study across multiple hospitals in Canada, and create a registry of pulmonary fibrosis patients.